

September 2016

MCPAP Releases Request for Proposals for MCPAP Regional Teams

Process

As we have previously reported, this past year MCPAP engaged in a strategic assessment of the program to evaluate how well MCPAP is meeting its purpose: to help pediatric primary care providers manage the behavioral health needs of their patients, specifically in light of the changing health care environment.

MCPAP and the Department of Mental Health (DMH), the primary funder of MCPAP, selected DMA Health Strategies (DMA) to conduct this strategic assessment which included more than 50 interviews with key stakeholders, analysis of 11 years of MCPAP utilization data, and a review of the myriad articles that have been published about MCPAP and other psychiatric consultation programs.

The assessment report is available on the MCPAP website at www.mcpap.com/About/ReportsNPublications.aspx.

Continued on page 2

In this Issue:

AAP Releases SBIRT Policy **3**

Opioid Use Disorders Statement Issued

Zero Suicide Goal
FDA Safety Announcement About Aripiprazole **4**

Leadership:

John Straus, MD
Founding Director

Barry Sarvet, MD
Medical Director

Marcy Ravech, MSW
Director



Request for Proposals *Continued from page 1*

The assessment report included a great deal of insight and information regarding MCPAP's performance and numerous potential opportunities for MCPAP to modify and enhance our infrastructure and services; many more opportunities than can be implemented within current resources. In order to solicit additional information on changes for MCPAP, MCPAP released a Request for Information (RFI) on March 27. The resulting feedback informed a subsequent Request for Proposals (RFP) for regional teams to deliver MCPAP services. Proposals were received on July 15, 2016 from all current providers of MCPAP services.

A carefully selected review committee, comprised of colleagues from the National Network of Child Psychiatry Access Projects (NNCPAP), DMH, and MCPAP Central Administration reviewed the proposals, and we are currently in negotiations with the parties involved.



Next Step

Once we identify a “go-live” date, we will provide you with information well in advance of any changes. All MCPAP-enrolled providers will receive formal communication that will explain what your practice will need to know with the new design of MCPAP including the enhanced services available to your practices. There will be multiple forms of communication regarding changes to the program, including webinars that will explain the new design.

It is our goal to ensure that our PCP practices continue to receive the same quality services you have come to expect from MCPAP. We greatly appreciate your patience during this time of change and thank you for your continued participation with MCPAP. Should you have any immediate questions or concerns please contact Marcy Ravech, Director of MCPAP at marcy.ravech@beaconhealthoptions.com or 617-350-1978.



AAP Releases Policy Statement Regarding SBIRT

In June 2016, the American Academy of Pediatrics released a policy statement regarding Substance Use Screening, Brief Intervention and Referral to Treatment (SBIRT):

The enormous public health impact of adolescent substance use and its preventable morbidity and mortality show the need for the health care sector, including pediatricians and the medical home, to increase its capacity related to substance use prevention, detection, assessment, and intervention. The American Academy of Pediatrics published its policy statement “Substance Use Screening, Brief Intervention, and Referral to Treatment for Pediatricians” in 2011 to introduce the concepts and terminology of screening, brief intervention, and referral to



treatment (SBIRT) and to offer clinical guidance about available substance use screening tools and intervention procedures. This policy statement is a revision of the 2011 SBIRT statement. An accompanying clinical report updates clinical guidance for adolescent SBIRT.

Access the
Clinical Report:

<http://pediatrics.aappublications.org/content/early/2016/06/16/peds.2016-1211>

AAP Releases Policy Statement on MAT for Opioid Use Disorder

The American Academy of Pediatrics recently released the following policy statement regarding Medication-Assisted Treatment of Adolescents with Opioid Use Disorder:

Opioid use disorder is a leading cause of morbidity and mortality among US youth. Effective treatments, both medications and substance use disorder counseling, are available but underused, and access to developmentally appropriate treatment is severely restricted for adolescents and young adults. Resources to disseminate available therapies and to develop new treatments specifically for this age group are needed to save and improve lives of youth with opioid addiction.

MCPAP’s web page on substance use:

www.mcpap.com/Provider/SubstanceUse.aspx

Full Policy Statement:

<http://pediatrics.aappublications.org/content/pediatrics/early/2016/08/18/peds.2016-1893.full.pdf>



Zero Suicide: An Aspirational Challenge

World Suicide Prevention Day was September 10, 2016. How do we prevent suicide? Is it preventable? Of people who have died by suicide, 45% had contact with primary care in the month prior, and 19% had contact with behavioral health in the month prior to the suicide. Zero Suicide is a central concept of the Surgeon General's 2012 National Strategy on Suicide Prevention. According to the Zero Suicide website, "The foundational belief of Zero Suicide is that suicide deaths for individuals under care within health and behavioral health systems are preventable. Zero Suicide is based on the realization that suicidal individuals often fall through the cracks in a fragmented, and often distracted, health care system. A systematic approach to quality improvement in these settings is both available necessary." The challenge of Zero Suicide cannot rely solely on practitioners but requires a system-wide approach. For World Suicide Prevention Day, we encourage you to visit the Zero Suicide

website at www.zerosuicide.sprc.org to learn more about this growing movement in health care. You can also view the recent MCPAP Clinical Conversation on Risk Assessment: Suicide Prevention in Pediatric Primary Care at www.mcpap.com/About/NewsNEvents.aspx. Additional references are available on our website at www.mcpap.com/Provider/SuicidePrevention.aspx.

If you would like additional training or information about suicide prevention please contact marcy.ravech@beaconhealthoptions.com.



U.S. Food and Drug Administration Releases Safety Announcement About Drug Aripiprazole:

The U.S. Food and Drug Administration (FDA) recently released a safety announcement about the mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada). The FDA is warning that compulsive or uncontrollable urges have been reported with the used of this antipsychotic drug. These uncontrollable urges were reported to have stopped when the medicine was discontinued or the dose was reduced. These impulse-control problems are rare, but they may result in harm to the patient and others if not recognized.



MCPAP wants all primary care providers to be aware of this new warning and to know that they can always call MCPAP with any questions regarding any medications.

For the full FDA warning, go to www.fda.gov/Drugs/DrugSafety/ucm498662.htm